Cybin Files Two Additional International Patent Applications in Support of the Company's Research Phase Programs
20 August 2021 - 12:34AM
InvestorsHub NewsWire
TORONTO, Canada -- August 19, 2021 -- InvestorsHub NewsWire
-- Cybin Inc. (NEO:CYBN)
(NYSE
AMERICAN:CYBN) ("Cybin" or the
"Company"), a biotechnology company focused on
progressing psychedelic therapeutics, today announced that it has
filed two additional international patent applications that bring
the potential to obtain patent coverage in 153 countries for each
of the patent applications.
The application, governed by the Patent Cooperation Treaty
("PCT"), grants the Company the right to file future national
applications into treaty member jurisdictions, including important
potential markets for the Company. The PCTs claim a library of
phenethylamine and derivative drug development candidates and
methods of use.
One of the PCT applications claims a group of proprietary
compounds identified by the Company's research data as being
important for further evaluation toward selection as potential
therapeutics. The other PCT application includes claims and
disclosures toward several other proprietary novel psychedelic
compounds, including compounds with positive research data, meeting
the Company's internal research metrics. The Company believes these
applications will further strengthen the CYB005 program, directed
to therapy resistant psychiatric disorders, and provide
compositions for further evaluation in additional future research
programs.
The Company continues to execute upon its three-pillar drug
development strategy to create: (a) a novel drug discovery platform
and research on the potential efficacy of psychedelic molecules to
address unmet mental health needs; (b) efficient drug delivery to
enhance dosing control; and (c) a potential novel treatment
regimen. These PCT applications are intended to provide broad
international patent protection of key intellectual property in
support of the Company's strategic objectives.
The Company's current indications include major depressive
disorder (CYB001), alcohol use disorder (CYB003) and anxiety
disorders (CYB004). In addition, two programs in the research phase
(CYB005 and CYB006) involved synthesis and testing of more than 50
novel compounds coupled with
extensive in-vitro and in-vivo pharmacokinetic,
receptor binding, behavioral and safety evaluations.
"Cybin is dedicated to finding treatments for therapy resistant
psychiatric indications as we believe these will provide patients
and their medical providers with new avenues to address this
significant unmet need. We appreciate the continued dedication of
our team to identify and progress our research phase programs
toward pre-clinical evaluation," said Doug Drysdale, CEO.
About Cybin
Cybin is a leading biotechnology company focused on progressing
psychedelic therapeutics by utilizing proprietary drug discovery
platforms, innovative drug delivery systems, novel formulation
approaches and treatment regimens for psychiatric disorders.
Cautionary Notes and Forward-Looking
Statements
Certain statements in this news release related to the Company
are forward-looking statements and are prospective in nature.
Forward-looking statements are not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as "may", "should", "could", "intend",
"estimate", "plan", "anticipate", "expect", "believe" or
"continue", or the negative thereof or similar variations.
Forward-looking statements in this news release include statements
regarding the Company's new strategic brand messaging campaign, and
psychedelic drug development programs to potentially treat mental
health disorders. There are numerous risks and uncertainties that
could cause actual results and Cybin's plans and objectives to
differ materially from those expressed in the forward-looking
information. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Cybin makes no medical, treatment or health benefit claims about
Cybin's proposed products. The U.S. Food and Drug Administration,
Health Canada or other similar regulatory authorities have not
evaluated claims regarding psilocybin, psychedelic tryptamine,
tryptamine derivatives or other psychedelic compounds or
nutraceutical products. The efficacy of such products have not been
confirmed by approved research. There is no assurance that the use
of psilocybin, psychedelic tryptamine, tryptamine derivatives or
other psychedelic compounds or nutraceuticals can diagnose, treat,
cure or prevent any disease or condition. Vigorous scientific
research and clinical trials are needed. Cybin has not conducted
clinical trials for the use of its proposed products. Any
references to quality, consistency, efficacy and safety of
potential products do not imply that Cybin verified such in
clinical trials or that Cybin will complete such trials. If Cybin
cannot obtain the approvals or research necessary to commercialize
its business, it may have a material adverse effect on Cybin's
performance and operations.
The NEO Exchange has neither approved nor disapproved the
contents of this news release and is not responsible for the
adequacy and accuracy of the contents herein.
Contacts
Investor:
Tim Regan/Scott Eckstein
KCSA Strategic Communications
Cybin@kcsa.com
Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com
Media:
John Kanakis
Cybin Inc.
John@cybin.com
Cybin (NEO:CYBN)
Historical Stock Chart
From May 2024 to Jun 2024
Cybin (NEO:CYBN)
Historical Stock Chart
From Jun 2023 to Jun 2024